News | March 04, 2009

FDA Clears Skin and Surface Treatment Applicator for Axxent Electronic Brachytherapy System

March 4, 2009 - Xoft Inc. said today the FDA cleared a skin and surface treatment applicator for use with the Axxent Electronic Brachytherapy (eBx) System to deliver surface brachytherapy, including Intraoperative Radiation Therapy (IORT).

This latest clearance allows the applicator to be used on any external or internal surface of the body where radiation therapy is indicated.

Previously cleared for accelerated treatment of early stage breast cancer and endometrial and rectal cancers, the Axxent System is also cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated. The proprietary Electronic Brachytherapy treatment platform is designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings under the supervision of a radiation oncologist.

"As market and clinical adoption for Electronic Brachytherapy grows for our breast and endometrial applications, the FDA clearance of skin and surface indications completely supports Xoft's mission of expanding the number of patients who can access radiation therapy and can dramatically benefit from it," said Michael Klein, president and CEO of Xoft. "Not only does it create access to a fast, convenient, non-isotope treatment option for millions of skin cancer patients, it continues to expand the clinical utility of the broad based Electronic Brachytherapy treatment platform that is being used at more than 50 radiation oncology centers across the U.S."

Skin cancer is the most common cancer in the U.S. with more than 1 million cases diagnosed annually. If diagnosed and treated early, most cases of skin cancer can be cured; however the National Cancer Institute estimates that skin cancer results in more than 10,000 deaths each year. Radiation therapy is one of several primary treatment options used to treat skin cancers, including surgery and chemotherapy. Designed to kill cancer cells and reduce the spread and local recurrence of cancer, radiation therapy is used alone or in combination with surgery or chemotherapy, depending on the location and stage of the cancer tumor as well as the patient's general health.

In addition to skin indications, the FDA clearance also covers surface indications, which means that many intraoperative radiation therapy procedures can be performed with the Xoft source, while surgery is being performed. Intraoperative treatment potentially reduces the time required for radiation therapy by delivering it immediately during surgery before any remaining cancer cells have a chance to grow. IORT, utilizing the Axxent System's miniaturized X-ray source that can deliver localized and targeted radiation treatment, is designed to minimize radiation exposure to surrounding healthy tissue and enables physicians and treating professionals to remain in the operating room with the patient.

For more information: www.xoftinc.com

Related Content

Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Elekta, Esteya electronic brachytherapy system, Radiation Oncology Centres, first in Australia, skin cancer
News | Brachytherapy Systems | January 16, 2017
On Dec. 8, 2016, a female patient in her 60s became the first in the Australia/New Zealand region to receive electronic...
iCAD, IORT boost, Xoft Axxent Electronic Brachytherapy System, intraoperative radiation therapy, whole breast radiation, early-stage breast cancer, SABCS 2016
News | Brachytherapy Systems | January 05, 2017
iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with...
Samsung, Neurologica, BodyTom CT scanner, Willis-Knighton Health System, Louisiana, La., brachytherapy, radiation therapy, ASTRO 2016
News | Computed Tomography (CT) | October 27, 2016
Samsung announced in September that the Willis-Knighton Cancer Center in Shreveport, La., added BodyTom CT, the world’s...
intermediate-risk prostate cancer, brachytherapy versus external beam therapy, radiation therapy, RT, ASTRO 2016
News | Brachytherapy Systems | October 25, 2016
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar...
Elekta, ASTRO 2016, HD Dynamic Radiosurgery, brachytherapy
News | Radiation Therapy | September 26, 2016
September 26, 2016 — At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept.
balloon catheter, IORT

The Xoft Axxent Controller, balloon and mini X-ray source assembled to simulate use during IORT. 

Feature | Women's Health | June 01, 2016 | By Barbara Schwartzberg, M.D., FACS
In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative...
global brachytherapy market value, MEDraysintell
News | Brachytherapy Systems | March 18, 2016
The global market for brachytherapy reached $705 million in 2015, according to a report from MEDraysintell.
Overlay Init